SHINE Medical Receives Approval for Construction Permit from NRC

SHINE Medical Technologies announced on February 25 that the U.S. Nuclear Regulatory Commission (NRC) authorized issuance of the SHINE construction permit. The construction permit makes SHINE the only U.S. medical isotope producer to reach this stage of the NRC regulatory pathway since the 1960s. It authorizes SHINE to build a facility for the production of molybdenum-99, which decays into technetium-99m, an agent used in millions of cardiac imaging procedures annually. The 57,000 sq. ft. facility will be located in Janesville, Wis. 
“This is the first time in over fifty years a medical isotope plant of the kind has been granted a construction permit. We've developed a greener, safer, and cheaper way to produce these life-saving isotopes on a global scale,” said SHINE CEO Greg Piefer, PhD.